You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 248 No. 11, September 17, 1982 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (30)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Detection of Metastatic Liver Disease

Use of Liver Scans and Biochemical Liver Tests

Margaret A. Tempero, MD; Richard J. Petersen, MD; Rowen K. Zetterman, MD; Henry M. Lemon, MD; Jud Gurney, MD

JAMA. 1982;248(11):1329-1332.


Abstract

The records of 94 patients with a known diagnosis of extrahepatic cancer having liver scan, biochemical liver tests (alkaline phosphatase, SGOT, lactic dehydrogenase, and bilirubin levels, and subsequent liver biopsy within a six-week period were reviewed. The sensitivity, specificity, and accuracy of the scan and biochemical tests in the detection of metastatic liver disease were calculated. The most sensitive single examination was the group of biochemical liver tests. Liver scans performed in the presence of normal biochemical test results were insensitive when compared with the liver scan alone or the liver scan in the presence of abnormal biochemical test results. The specificity and accuracy of all tests and test combinations were statistically equivalent. Screening for hepatic metastases in patients with cancer is best accomplished with the more sensitive and less expensive group of biochemical liver tests, reserving the liver scan for those patients with abnormal biochemical test results.

(JAMA 1982;248:1329-1332)



Author Affiliations

From the Sections of Oncology (Drs Tempero and Lemon) and Gastroenterology (Dr Zetterman), Department of Internal Medicine, and the Department of Radiology (Dr Gurney), University of Nebraska Medical Center, and the Department of Radiology, Bishop Clarkson Memorial Hospital (Dr Petersen), Omaha.


Footnotes

Reprint requests to Section of Oncology, Department of Internal Medicine, University of Nebraska Medical Center, 42nd Street and Dewey Avenue, Omaha, NE 68105 (Dr Tempero).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Methodological Standards in Diagnostic Test Research: Getting Better but Still Not Good
Reid et al.
JAMA 1995;274:645-651.
ABSTRACT  

Evaluation of Head and Neck Cancer Patients: A National Survey
Swann and Blakeslee
Arch Otolaryngol Head Neck Surg 1988;114:775-778.
ABSTRACT  

A Case Study of Physicians' Use of Liver-Spleen Scans: Are We Doing What We Think We're Doing?
Steinberg et al.
Arch Intern Med 1986;146:253-258.
ABSTRACT  

Diagnosis of Metastatic Liver Cancer-Reply
Silberstein
JAMA 1984;252:1280-1280.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.